6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of November 12, 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,333-248980 and 333-228671)and our Registration Statements on Form F-3 (Files No. 333-274816,333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Alterity to Present at the Bell Potter Healthcare Conference |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey<br> P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: November 12, 2025
2
Exhibit 99.1
Alterity Therapeutics to Present at the BellPotter Healthcare Virtual Conference
MELBOURNE,AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies.
Presentation details
AUSTRALIA PARTICIPANTS:
| Date: | Wednesday, 19 November 2025 |
|---|---|
| Time: | 1:30 p.m. AEDT (Sydney/Melbourne) |
UNITED STATES PARTICIPANTS:
| Date: | Tuesday, 18 November 2025 |
|---|---|
| Time: | 6:30 p.m. Pacific Time |
| 9:30 p.m. Eastern Time |
Currentand interested shareholders can register for the webcast here: Bell Potter | Healthcare 2025 (EXT)
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Remy Bernarda
Investor Relations Advisory Solutions
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
+1 (646) 577-8520
Forward Looking Statements
This press release contains “forward-lookingstatements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,”“anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” andother similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could causeactual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “RiskFactors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports onForm 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but notlimited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limitedto, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but notlimited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval,production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company toprocure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drugcompounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patentprotection for the Company’s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patentrights and the uncertainty of the Company freedom to operate.
Any forward-looking statement madeby us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,whether as a result of new information, future developments or otherwise.